Is Pfizer Stock a Buy?
Pfizer (NYSE: PFE) isn't exactly a hot stock right now. Since its massive run-up during the pandemic's height, built on hopes for its coronavirus vaccine, new sources of growth haven't led to equally outsized windfalls.
But for investors, it could still be a great pickup once a few of the loftier expectations about its future are safely in check. Let's start by hearing from the bears about why the stock isn't a buy, and then look at the other side's argument.
Under normal conditions, one might expect that a big pharma business, with a large portfolio of essential drugs and a recent run of best-selling medicines like the Comirnaty coronavirus vaccine, would be booming. In such a scenario, the investing thesis would be obvious -- buy the stock, because the company has a knack for making it go up consistently over time by successfully developing the right drugs for the right markets.
Source Fool.com
Pfizer Inc. Stock
With 14 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
With a target price of 27 € there is a positive potential of 25.44% for Pfizer Inc. compared to the current price of 21.53 €.
